Switch from aprotinin to ε-aminocaproic acid: Impact on blood loss, transfusion, and clinical outcome in neonates undergoing cardiac surgery

British Journal of Anaesthesia

Volumn 107, Issue 6, 2011, Pages 934-939

  Martin, K ^a   Gertler, R ^a   Liermann, H ^a   Mayr, N P ^a   MacGuill, M ^a   Schreiber, C ^a   Vogt, M ^a   Tassani, P ^a   Wiesner, G ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

antifibrinolytics; cardiac surgical procedures; cardiopulmonary bypass; Epsilon aminocaproic acid; neonates

Indexed keywords

AMINOCAPROIC ACID; APROTININ;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART SURGERY; HUMAN; INCIDENCE; INFANT; INTENSIVE CARE UNIT; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REOPERATION; SURGICAL RISK; TREATMENT OUTCOME;

EID: 81855206568     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aer267     Document Type: Article

References (27)

1. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. Can Med Assoc J 2009; 180: 183-93
2. Eaton MP. Antifibrinolytic therapy in surgery for congenital heart disease. Anesth Analg 2008; 106: 1087-100
3. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83: S27-86
4. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-31
5. Health Canada. Important Safety Information and availability of Trasylol (aprotinin)-Notice to Hospitals. 2007. Available from www.hc-sc.gc.ca/dhp-mps/ medeff/advisories-avis/prof/-2007/ trasylol-nth-aah-2-eng.php
6. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-11
7. Ririe DG, James RL, O'Brien JJ, et al. The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects. Anesth Analg 2002; 94: 44-9, table of contents
8. Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg 2002; 123: 110-8
9. Lacour-Gayet F, Clarke D, Jacobs J, et al. The Aristotle score: a complexity-adjusted method to evaluate surgical results. Eur J Cardiothorac Surg 2004; 25: 911-24
10. Akcan-Arikan A, Zappitelli M, Loftis LL,Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 2007; 71: 1028-35
11. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34: 571-90
12. Szekely A, Sapi E, Breuer T, et al. Aprotinin and renal dysfunction after pediatric cardiac surgery. Paediatr Anaesth 2008; 18: 151-9
13. Chauhan S, Kumar BA, Rao BH, et al. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. Ann Thorac Surg 2000; 70: 1308-12
14. McClure PD, Izsak J. The use of epsilon-aminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease. Anesthesiology 1974; 40: 604-8
15. Rao BH, Saxena N, Chauhan S, Bisoi AK, Venugopal P. Epsilon aminocaproic acid in paediatric cardiac surgery to reduce postoperative blood loss. Indian J Med Res 2000; 111: 57-61
16. Zonis Z, Seear M, Reichert C, Sett S, Allen C. The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 1996; 111: 982-7
17. Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Efficacy of epsilon-aminocaproic acid in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1999; 13: 304-8
18. Mossinger H, DietrichW, Braun SL, Jochum M, Meisner H, Richter JA. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003; 75: 430-7
19. Williams GD, Ramamoorthy C, Pentcheva K, Boltz MG, Kamra K, Reddy VM. A randomized, controlled trial of aprotinin in neonates undergoing open-heart surgery. Paediatr Anaesth 2008; 18: 812-9
20. Carrel TP, Schwanda M, Vogt PR, Turina MI. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998; 66: 153-8
21. Guzzetta NA, Evans FM, Rosenberg ES, et al. The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis. Anesth Analg 2009; 108: 448-55
22. Furnary AP, Wu Y, Hiratzka LF, Grunkemeier GL, Page US 3rd. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 2007; 116: I127-33
23. Breuer T, Martin K, Wilhelm M, et al. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg 2009; 35: 167-71
24. Moore RA, McNicholas KW, Naidech H, Flicker S, Gallagher JD. Clinically silent venous thrombosis following internal and external jugular central venous cannulation in pediatric cardiac patients. Anesthesiology 1985; 62: 640-3
25. Rabinovici R, Heyman A, Kluger Y, Shinar E. Convulsions induced by aminocaproic acid infusion. DICP 1989; 23: 780-1
26. Petaja J, Peltola K. Venous thrombosis in pediatric cardiac surgery. J Cardiothorac Vasc Anesth 1997; 11: 889-94
27. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107: 1783-90